The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada | Zendy

Iman Zandieh | Zendy; Darin Krygier | Zendy; Victor Wong | Zendy; John M. Howard | Zendy; Lawrence Worobetz | Zendy; Gerald Y. Minuk | Zendy; Helga Witt-Sullivan | Zendy; Eric M. Yoshida | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada

Author(s) -

Iman Zandieh,

Darin Krygier,

Victor Wong,

John M. Howard,

Lawrence Worobetz,

Gerald Y. Minuk,

Helga Witt-Sullivan,

Eric M. Yoshida

Publication year - 2008

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2008/509459

Subject(s) - budesonide , azathioprine , medicine , prednisone , autoimmune hepatitis , gastroenterology , adverse effect , glucocorticoid , prednisolone , hepatitis , corticosteroid , disease

Autoimmune hepatitis (AIH) is a chronic inflammatory disease that is successfully treated with prednisone and/or azathioprine immunosuppressive therapy in 70% to 80% of patients. The remaining patients are intolerant or refractory to these standard medications. Budesonide, a synthetic glucocorticoid, undergoes a high degree of first-pass metabolism, reducing its systemic bioavailability, and has a 15-fold greater affinity for the glucocorticoid receptor than prednisolone. Budesonide may be a potentially useful systemic steroid-sparing immunosuppressive agent in the treatment of AIH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research